Development and validation of a drug adherence index for COPD

Development and validation of a drug adherence index for COPD

BACKGROUND: Inhaled medications are the mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite their importance, adherence to these medications is low. Low adherence is linked to increased exacerbation rates, mortality rates, health care utilization, and, ultimately, increas...

Full description

Bibliographic Details
Main Authors: Bancroft, T. (Author), Bengtson, L.G.S (Author), Buikema, A.R (Author), Schilling, C. (Author), Stanford, R.H (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
aclidinium bromide
administrative claims (health care)
Administrative Claims, Healthcare
adult
Adult
aged
Aged
Aged, 80 and over
agents interacting with transmitter, hormone or drug receptors
antiinflammatory agent
antilipemic agent
Article
assessment of humans
bronchodilating agent
Bronchodilator Agents
central nervous system agents
cholinergic receptor blocking agent
chronic obstructive lung disease
controlled study
corticosteroid
drug adherence index
female
Female
human
Humans
hydroxymethylglutaryl coenzyme A reductase inhibitor
ipratropium bromide
ipratropium bromide plus salbutamol
Logistic Models
major clinical study
male
Male
medicare
Medicare Part C
Medication Adherence
medication compliance
methylxanthine
middle aged
Middle Aged
observational study
outcome assessment
patient compliance
patient identification
Pharmaceutical Services
pharmacy (shop)
phosphodiesterase inhibitor
prescription
procedures
Pulmonary Disease, Chronic Obstructive
Retrospective Studies
retrospective study
risk assessment
Risk Assessment
roflumilast
spasmolytic agent
statistical model
tiotropium bromide
treatment refusal
umeclidinium
umeclidinium plus vilanterol
United States
validation process
very elderly
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items